BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22964035)

  • 61. Comparison of nucleostemin gene expression in CD133+ and CD133- cell population in colon cancer cell line HT29.
    Zia-Jahromi N; Hejazi SH; Panjepour M; Parivar K; Gharagozloo M
    J Cancer Res Ther; 2014; 10(1):68-72. PubMed ID: 24762489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
    Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
    J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line.
    Feng JM; Miao ZH; Jiang Y; Chen Y; Li JX; Tong LJ; Zhang J; Huang YR; Ding J
    Cancer Biol Ther; 2012 Dec; 13(14):1396-406. PubMed ID: 22954703
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
    Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
    Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
    Wu B; Sun C; Feng F; Ge M; Xia L
    J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma.
    Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Mori T; Yoshii H; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
    Nucl Med Biol; 2011 Feb; 38(2):151-7. PubMed ID: 21315269
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of stem cell quantification in stage II colon cancer.
    Vaz MA; Martinez JC; Devesa JM; Trill JD; Abraira V; Riquelme A; Carrato A
    PLoS One; 2014; 9(2):e88480. PubMed ID: 24586330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis.
    Nagata H; Ishihara S; Kishikawa J; Sonoda H; Murono K; Emoto S; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Kawai K; Nozawa H
    Int J Oncol; 2018 Mar; 52(3):721-732. PubMed ID: 29328371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
    Hagiwara S; Kudo M; Ueshima K; Chung H; Yamaguchi M; Takita M; Haji S; Kimura M; Arao T; Nishio K; Park AM; Munakata H
    J Gastroenterol; 2011 Feb; 46(2):212-21. PubMed ID: 20683621
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study.
    Kojima M; Ishii G; Atsumi N; Fujii S; Saito N; Ochiai A
    Cancer Sci; 2008 Aug; 99(8):1578-83. PubMed ID: 18754869
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer.
    Puglisi MA; Sgambato A; Saulnier N; Rafanelli F; Barba M; Boninsegna A; Piscaglia AC; Lauritano C; Novi ML; Barbaro F; Rinninella E; Campanale C; Giuliante F; Nuzzo G; Alfieri S; Doglietto GB; Cittadini A; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():55-62. PubMed ID: 19530513
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
    Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
    Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.
    Saricanbaz I; Karahacioglu E; Ekinci O; Bora H; Kilic D; Akmansu M
    Asian Pac J Cancer Prev; 2014; 15(19):8215-9. PubMed ID: 25339008
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma.
    Sharma BK; Manglik V; O'Connell M; Weeraratna A; McCarron EC; Broussard JN; Divito KA; Simbulan-Rosenthal CM; Rosenthal DS; Zapas JL
    Int J Oncol; 2012 Nov; 41(5):1570-6. PubMed ID: 22922842
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.
    Yeh CT; Kuo CJ; Lai MW; Chen TC; Lin CY; Yeh TS; Lee WC
    BMC Cancer; 2009 Sep; 9():324. PubMed ID: 19744348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.